DSpace university logo mark
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 130 病院 > 130 学術雑誌論文 >

Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema

ファイル 記述 サイズフォーマット
CliOph12_1845.pdf1.01 MBAdobe PDF本文ファイル

タイトル: Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema
著者: Tsuiki, Eiko / Suzuma, Kiyoshi / Matsumoto, Makiko / Mohamed, Yasser Helmy / Kitaoka, Takashi
発行日: 2018年12月
出版者: Dove Medical Press Ltd
引用: Clinical Ophthalmology, 12, pp.1845-1852; 2018
抄録: Purpose: This study was designed to investigate the therapeutic effects of oral kallidinogenase medication as an adjuvant therapy in treating patients with diabetic macular edema (DME). Study design: This was a prospective, open-labeled, randomized study. Methods: All patients were given posterior sub-Tenon triamcinolone acetonide (STTA) injection and focal laser treatment session for DME. The patients were subdivided into two groups: 1) those treated with oral kallidinogenase for at least 6 months after local treatment(treated group) and 2) those treated without oral kallidinogenase (untreated group). In this study, best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and chorioretinal blood flow level were measured in 17 patients (19 eyes). Chorioretinal blood flow levels at the disc and macula were measured by laser speckle flowgraphy and evaluated using the mean blur rate (MBR). These data were measured at baseline and at 1, 3, and 6 months after treatment initiation. Results: BCVA at 6 months after treatment significantly improved in treated group (P,0.05).But the mean CRT after treatment significantly decreased in both groups. There was no significant difference in the mean SCT at baseline between the two groups. The mean SCT after treatment in treated group was significantly thinner than that before treatment(P,0.05). Compared to baseline (100%), MBR at the disc and the macula at 6 months after treatment significantly decreased to 84.8% and 86.2%, respectively, in untreated group (P,0.05), though it remained unchanged at 98.7% and 99.7% in treated group.Conclusion: Oral kallidinogenase medication is useful as an adjuvant therapy to enhance the therapeutic effect of STTA in DME patients.
キーワード: Diabetic macular edema / Enhanced depth imaging optical coherence tomography / Kallidinogenase / Laser speckle flowgraphy
URI: http://hdl.handle.net/10069/38746
ISSN: 11775467
DOI: 10.2147/OPTH.S168420
権利: © 2018 Tsuiki et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
資料タイプ: Journal Article
原稿種類: publisher
出現コレクション:130 学術雑誌論文

引用URI : http://hdl.handle.net/10069/38746



Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace